semaglutide mash approval 🎉Exciting news that is now FDA approved for (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% Semaglutide approved for MASH treatment:

The Phase 2 trial , published in the New England Journal of Medicine, tested doses from 1 mg to 12 mg over 48 weeks

These challenges can lead to early generic entry if successful, but so far, no court rulings have cleared the way for generics in the U.S

Through a collaborative partnership between its medical and data science teams, Munich Re Life US has undertaken a large-scale study to further understand the potential significance of GLP-1 drugs

If it isnt appropriate, they wont prescribe it

Feriz-Bonelo, Erica Yama-Mosquera, Alex H

Ruolo clinico: opzione low-risk o di mantenimento nei pazienti che non tollerano altre classi